{"data":[{"accessionNo":"0001193125-26-352639","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":1489443,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0001193125-26-352639","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":1489443,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0001193125-26-352639","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":1489443,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Shabet Rose Sharon","reportingCik":null,"personType":"IN","sharesOwned":1383621,"percentOfClass":9.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":null,"personType":"PN","sharesOwned":1383621,"percentOfClass":9.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1383621,"percentOfClass":9.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":null,"personType":"IN","sharesOwned":1383621,"percentOfClass":9.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1303208,"percentOfClass":8.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1250816,"percentOfClass":8.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":null,"personType":"PN","sharesOwned":1250816,"percentOfClass":8.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0001193805-26-001095","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Schonfeld Strategic Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":781678,"percentOfClass":5.33,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities Drawdown Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":80413,"percentOfClass":0.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities Drawdown GP LLC","reportingCik":null,"personType":"OO","sharesOwned":80413,"percentOfClass":0.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Viking Global Opportunities Drawdown (Aggregator) LP","reportingCik":null,"personType":"PN","sharesOwned":80413,"percentOfClass":0.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-003736","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"KAVRA 104 LLC","reportingCik":null,"personType":"OO","sharesOwned":52392,"percentOfClass":0.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000070858-26-000398","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BANK OF AMERICA CORP /DE/","reportingCik":null,"personType":"HC","sharesOwned":857318,"percentOfClass":5.9,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":null,"personType":"PN","sharesOwned":1461633,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1461633,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":null,"personType":"IN","sharesOwned":1461633,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Shabet Rose Sharon","reportingCik":null,"personType":"IN","sharesOwned":1461633,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0001193125-26-226567","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-03-31","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":1461105,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0001193125-26-226567","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-03-31","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":1461105,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0001193125-26-226567","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-03-31","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":1461105,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1358769,"percentOfClass":9.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1291751,"percentOfClass":8.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":null,"personType":"PN","sharesOwned":1291751,"percentOfClass":8.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Drawdown Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":102864,"percentOfClass":0.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Drawdown (Aggregator) LP","reportingCik":null,"personType":"PN","sharesOwned":102864,"percentOfClass":0.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Drawdown GP LLC","reportingCik":null,"personType":"OO","sharesOwned":102864,"percentOfClass":0.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-002437","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":"45720N103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"KAVRA 104 LLC","reportingCik":null,"personType":"OO","sharesOwned":67018,"percentOfClass":0.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":null,"personType":"PN","sharesOwned":1454608,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1454608,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Shabet Rose Sharon","reportingCik":null,"personType":"IN","sharesOwned":1454608,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":null,"personType":"IN","sharesOwned":1454608,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Ott David C.","reportingCik":null,"personType":"IN","sharesOwned":1454608,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1351744,"percentOfClass":9.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":null,"personType":"PN","sharesOwned":1284726,"percentOfClass":8.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1284726,"percentOfClass":8.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Drawdown Portfolio GP LLC","reportingCik":null,"personType":"OO","sharesOwned":102864,"percentOfClass":0.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Drawdown (Aggregator) LP","reportingCik":null,"personType":"PN","sharesOwned":102864,"percentOfClass":0.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Viking Global Opportunities Drawdown GP LLC","reportingCik":null,"personType":"OO","sharesOwned":102864,"percentOfClass":0.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000905148-26-000883","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"KAVRA 104 LLC","reportingCik":null,"personType":"OO","sharesOwned":67018,"percentOfClass":0.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000895421-26-000038","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":1155416,"percentOfClass":7.9,"filedAt":"2026-02-11","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0000895421-26-000038","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley Capital Services LLC","reportingCik":null,"personType":"BD,CO","sharesOwned":918011,"percentOfClass":6.3,"filedAt":"2026-02-11","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0002012383-26-000675","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002007919","issuerName":"INHIBRX BIOSCIENCES, INC.","ticker":"INBX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":768130,"percentOfClass":5.3,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"},{"accessionNo":"0002012383-25-002589","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002007919","issuerName":"Inhibrx Biosciences, Inc.","ticker":"INBX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":680368,"percentOfClass":4.7,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/inbx"}],"updatedAt":"2026-10-23T20:38:14.951Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/inbx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}